ATE260096T1 - Agglomerate durch kristallisation - Google Patents

Agglomerate durch kristallisation

Info

Publication number
ATE260096T1
ATE260096T1 AT00917035T AT00917035T ATE260096T1 AT E260096 T1 ATE260096 T1 AT E260096T1 AT 00917035 T AT00917035 T AT 00917035T AT 00917035 T AT00917035 T AT 00917035T AT E260096 T1 ATE260096 T1 AT E260096T1
Authority
AT
Austria
Prior art keywords
agglomerates
crystalization
lactum
solvents
suspension
Prior art date
Application number
AT00917035T
Other languages
English (en)
Inventor
Johannes Booij
Ageeth Geertruida Lefferts
Original Assignee
Dsm Ip Assets Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8240058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE260096(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dsm Ip Assets Bv filed Critical Dsm Ip Assets Bv
Application granted granted Critical
Publication of ATE260096T1 publication Critical patent/ATE260096T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D503/00—Heterocyclic compounds containing 4-oxa-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxapenicillins, clavulanic acid derivatives; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Cephalosporin Compounds (AREA)
AT00917035T 1999-04-01 2000-04-03 Agglomerate durch kristallisation ATE260096T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99201034 1999-04-01
PCT/EP2000/002917 WO2000041478A2 (en) 1999-04-01 2000-04-03 Agglomerates by crystallisation

Publications (1)

Publication Number Publication Date
ATE260096T1 true ATE260096T1 (de) 2004-03-15

Family

ID=8240058

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00917035T ATE260096T1 (de) 1999-04-01 2000-04-03 Agglomerate durch kristallisation

Country Status (12)

Country Link
US (3) US6979735B1 (de)
EP (1) EP1165049B2 (de)
CN (1) CN1209099C (de)
AT (1) ATE260096T1 (de)
AU (1) AU3817300A (de)
CA (1) CA2364342C (de)
DE (1) DE60008508T9 (de)
ES (1) ES2215628T5 (de)
MX (1) MXPA01009808A (de)
SI (1) SI1165049T2 (de)
TR (1) TR200102771T2 (de)
WO (1) WO2000041478A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US7250176B1 (en) 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
WO2002030392A2 (en) 2000-10-12 2002-04-18 Beecham Pharmaceuticals (Pte) Limited Formulation containing amoxicillin
MXPA03003312A (es) * 2000-10-20 2004-12-03 Biochemie Gmbh Composiciones farmaceuticas.
GB0031267D0 (en) * 2000-12-21 2001-01-31 Smithkline Beecham Plc Novel compositions
AU2002315287A1 (en) * 2001-04-12 2002-10-28 Sandoz Gmbh Pharmaceutical composition comprising clavulanic acid
AT500131A1 (de) * 2002-02-01 2005-11-15 Sandoz Ag Organische verbindungen
AT500134A1 (de) * 2002-02-01 2005-11-15 Sandoz Ag Verfahren zur herstellung eines entmischungsstabilen granulats
AT500132A1 (de) * 2002-02-06 2005-11-15 Sandoz Ag Organische verbindungen
AT500133A1 (de) * 2002-02-06 2005-11-15 Sandoz Ag Verfahren zur herstellung eines entmischungsstabilen granulats
US7534781B2 (en) 2003-03-21 2009-05-19 Dsm Ip Assets B.V. Crystalline amoxicillin trihydrate powder
CN102260278B (zh) * 2003-03-21 2015-05-06 中化帝斯曼制药有限公司荷兰公司 三水羟氨苄青霉素结晶粉末
EA012296B1 (ru) * 2004-01-06 2009-08-28 Панацея Биотек Лтд. Фармацевтическая композиция с контролируемым высвобождением, содержащая не растворимый в кислотах полимер и биоадгезивный полимер
AU2015374114B2 (en) 2014-12-29 2018-07-26 Bioventus, Llc Systems and methods for improved delivery of osteoinductive molecules in bone repair
CN108905264A (zh) * 2018-07-17 2018-11-30 凯莱英医药集团（天津）股份有限公司 连续化结晶方法在β-内酰胺类抗生素合成中的应用及连续化结晶系统
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CA3110111A1 (en) 2018-08-09 2020-02-13 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3697506A (en) * 1970-08-07 1972-10-10 Pfizer Crystalline alkali metal salts of {60 -carboxybenzylpenicillin and process therefor
US3692781A (en) * 1971-02-26 1972-09-19 Glaxo Lab Ltd Recovery of pure cephalexin from acidic reaction mixtures
US4138555A (en) * 1971-05-14 1979-02-06 Glaxo Laboratories, Limited (6R,7R)-7-[2-aryl-2-(etherified oximino)acetamido]-3-carbamoyloxymethylceph-3-em-4-carboxylic acid 1-oxides
AR206201A1 (es) * 1972-06-29 1976-07-07 Ciba Geigy Ag Procedimiento para la obtencion de compuestos de acido 7beta-amino-3-cefem-3-01-4-carboxilico0-substituidos
US3932386A (en) * 1973-06-18 1976-01-13 American Home Products Corporation Sodium 6-(L-aminocyclohexane carboxamido)penicillanic acid
GB1563103A (en) * 1975-10-13 1980-03-19 Beecham Group Ltd Process for the preparation of clavulanic acid
NZ189022A (en) * 1977-12-08 1981-11-19 Beecham Group Ltd Pharmaceutically acceptable particles of clavulanates dispersed in a polymeric binder
US4454069A (en) * 1979-08-24 1984-06-12 Beecham Group Limited Clavulanic acid salts and their preparation from the tertiary butyl amine salt
DE3169452D1 (en) * 1980-12-09 1985-04-25 Beecham Group Plc Derivatives of clavulanic acid, their preparation and their use
US4522701A (en) * 1982-02-11 1985-06-11 E. I. Du Pont De Nemours And Company Process for preparing an anisotropic aromatic pitch
US4456753A (en) 1983-02-07 1984-06-26 Pfizer Inc. Process for the manufacture of highly crystalline sodium cefoperazone
DE3314725A1 (de) * 1983-04-22 1984-10-25 Siemens AG, 1000 Berlin und 8000 München Oberflaechenwellen-resonatorfilter
US4659812A (en) * 1985-08-20 1987-04-21 Bristol-Myers Company Cephalosporin intermediates
GB8608962D0 (en) * 1986-04-12 1986-05-14 Beecham Group Plc Beta-lactam antibiotics
US5288861A (en) * 1987-01-29 1994-02-22 Beecham Group Plc Potassium clavulanate in rosette form
DK175709B1 (da) 1987-01-29 2005-01-31 Beecham Group Plc Fremgangsmåde til fremstilling af kalium-clavulanat
EP0433428B1 (de) 1989-07-10 1994-10-12 Chemferm V.O.F. Stabile form von cephradin, verfahren zu dessen herstellung und darin verwendete zwischenprodukte
GB9009473D0 (en) 1990-04-27 1990-06-20 Beecham Group Plc Pharmaceutical formulation
US5250525A (en) * 1991-02-12 1993-10-05 Pliva Handels Gmbh 4-oxo-azetidine-2-sulfonic acids and their salts, processes for the preparation thereof and their use
GB9109862D0 (en) 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
AT400033B (de) * 1992-03-10 1995-09-25 Biochemie Gmbh Neues verfahren zur isolierung und reinigung von clavulansäure und zur herstellung von pharmakologisch verträglichen salzen derselben
AT401871B (de) † 1994-01-28 1996-12-27 Gebro Broschek Gmbh Verfahren zur herstellung von s(+)-ibuprofen- partikeln mit verbesserten fliesseigenschaften und deren verwendung zur arzneimittelherstellung
SI9400107A (en) * 1994-03-02 1995-10-31 Lek Tovarna Farmacevtskih New process of the isolation of clavulanic acid and its pharmaceutical salts from fermented broth of streptomyces sp.p 6621 ferm p 2804.
GB9408117D0 (en) 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
DE4426973C1 (de) * 1994-07-29 1996-03-28 Degussa Verfahren zur Herstellung eines als Brennstoffzellenelektrode einsetzbaren Plattinlegierungskatalysators
TWI225402B (en) * 1996-03-13 2004-12-21 Biochemie Gmbh Auxiliary-free agglomerates
US6414142B1 (en) 1996-06-13 2002-07-02 Smithkline Beecham Corporation Process for preparing potassium clavulanate
AU4011397A (en) 1996-07-16 1998-02-09 Gist-Brocades B.V. Beta-lactam granules free of organic solvents
GB9616536D0 (en) † 1996-08-06 1996-09-25 Quadrant Holdings Cambridge Co-amoxiclav dosage form
TR199901631T2 (xx) 1996-11-11 1999-09-21 Gist-Brocades B.V. Klavülanik asitin esterleri ve tuzlarının hazırlanması için işlem.
ES2142641T3 (es) * 1997-03-24 2000-04-16 Cipan Comp Ind Prod Procedimiento para aislar una sal alcalino-metalica farmaceuticamente aceptable del acido clavulanico.
AU9540898A (en) † 1997-08-29 1999-03-22 Dsm N.V. Granules free of excipients

Also Published As

Publication number Publication date
DE60008508T3 (de) 2012-01-19
US6979735B1 (en) 2005-12-27
CA2364342C (en) 2011-02-01
WO2000041478A3 (en) 2000-11-02
SI1165049T2 (sl) 2011-11-30
US20110045082A1 (en) 2011-02-24
CA2364342A1 (en) 2000-07-20
SI1165049T1 (en) 2004-12-31
CN1345231A (zh) 2002-04-17
EP1165049A2 (de) 2002-01-02
DE60008508T9 (de) 2012-06-14
EP1165049B1 (de) 2004-02-25
MXPA01009808A (es) 2002-04-24
DE60008508T2 (de) 2004-12-23
TR200102771T2 (tr) 2002-04-22
AU3817300A (en) 2000-08-01
WO2000041478A2 (en) 2000-07-20
ES2215628T5 (es) 2011-11-28
US20060079496A1 (en) 2006-04-13
CN1209099C (zh) 2005-07-06
EP1165049B2 (de) 2011-07-06
DE60008508D1 (de) 2004-04-01
ES2215628T3 (es) 2004-10-16

Similar Documents

Publication Publication Date Title
ATE260096T1 (de) Agglomerate durch kristallisation
WO2002074767A8 (en) Metalloproteinase inhibitors
DK1537097T3 (da) Fremgangsmåde til fremstilling af 3-Halo-4,5-dihydro-1H-pyrazoler
WO2004011447A3 (en) Method for preparing fused oxazinones from ortho-amino aromatic carboxylic acid and a carboxylic acid in the presence of a sulfonyl chloride and pyridine
WO2004078923A3 (en) Pyk2 crystal structure and uses
EP0931788A3 (de) Metalloproteinase-Inhibitoren
WO2003006425A3 (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
WO2001017973A3 (de) Neue herbizide
WO2002074752A8 (en) Metalloproteinase inhibitors
DK1341728T3 (da) Fremgangsmåde til inaktivering af slam
WO2002083616A1 (en) α-SUBSTITUTED φ-ARYLFATTY ACID DERIVATIVE
EP1555261A4 (de) Valerolactonverbindungen und parf mzusammensetzung
WO2002016322A3 (en) Process for the preparation of 2-aminoethylpyridines
WO2000071553A8 (en) Novel aluminosiloxane compound and process for preparing the same
WO2003029254A1 (en) Process for preparation of tricyclic compounds
EP1355966B8 (de) Mit aktinischer strahlung aktivierbare blends aus kristallinen und amorphen verbindungen, verfahren zu ihrer herstellung und ihre verwendung
BR0009453A (pt) Processo para a preparação de um composto
NO20051009L (no) Syntese av indoliziner
EE05136B1 (et) Asendatud imidasopridiinhendite valmistamise meetod
WO1998034584A3 (en) Compounds and method for preparing substituted 4-phenyl-4-cyanocyclohexanoic acids
WO2006006040A3 (en) News diamine salts of cephalosporin antibiotics and their preparation
ID27440A (id) Proses untuk menyiapkan penengah-penengah
SE0101323D0 (sv) New process
EP1489091A4 (de) Verfahren zur herstellung eines triterpenderivats
ATE286497T1 (de) Herstellung von hydroxyverbindungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1165049

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 1165049

Country of ref document: EP